| Literature DB >> 29777925 |
T D A Ly1, S Edouard1, S Badiaga1, H Tissot-Dupont1, V T Hoang1, V Pommier de Santi2, P Brouqui1, D Raoult1, P Gautret3.
Abstract
OBJECTIVES: To assess risk factors for respiratory tract infection symptoms and signs in sheltered homeless people in Marseille during the winter season, including pathogen carriage.Entities:
Keywords: Homeless; Quantitative polymerase chain reaction; Quantitative reverse transcription–polymerase chain reaction; Respiratory pathogen carriage; Respiratory symptoms and signs
Mesh:
Year: 2018 PMID: 29777925 PMCID: PMC7128312 DOI: 10.1016/j.cmi.2018.04.032
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 8.067
Risk factors for respiratory disease: univariate analysis
| Characteristics | Total ( | At least one respiratory symptom or sign | No respiratory symptom and no sign | Univariate analysis |
|---|---|---|---|---|
| Total | 168 (35.3) | 308 (64.3) | ||
| Year of study | ||||
| 2015 | 125 (26.1) | 37 (29.6) | 88 (70.4) | |
| 2016 | 156 (32.6) | 74 (47.4) | 82 (52.6) | |
| 2017 | 198 (41.3) | 57 (29.2) | 138 (70.8) | |
| Shelter | ||||
| A | 311 (64.9) | 107 (35.2) | 201 (65.3) | 0.93 (0.63–1.38), p 0.73 |
| B | 168 (35.1) | 61 (36.3) | 107 (63.7) | Ref |
| Age | ||||
| Mean age (SD) | 43.6 ± 16 years | NA | ||
| Age range | 18–84 years | NA | ||
| ≤50 years of age | 318 (66.8) | 98 (30.8) | 220 (69.2) | Ref |
| >50 years of age | 158 (33.2) | 69 (44.2) | 87 (55.8) | 1.78 (1.20–2.64), p 0.004 |
| Birthplace | ||||
| France (mainland) | 71 (14.8) | 39 (54.9) | 32 (45.1) | Ref |
| France (overseas territories) | 1 (0.2) | 0 (0) | 1 (100) | NA |
| North Africa | 300 (62.6) | 100 (33.4) | 199 (66.6) | 0.41 (0.25–0.70), p 0.001 |
| Sub-Saharan Africa | 43 (9.0) | 7 (16.3) | 36 (83.7) | 0.16 (0.63–0.41), p <0.0001 |
| East Europe | 35 (7.3) | 13 (39.4) | 20 (60.6) | 0.53 (0.23–1.24), p 0.14 |
| West Europe | 9 (1.9) | 2 (22.2) | 7 (77.8) | 0.23 (0.04–1.21), p 0.08 |
| Asia | 20 (4.2) | 7 (35.0) | 13 (65.0) | 0.44 (0.16–1.24), p 0.12 |
| Other | 0 (0) | NA | ||
| Mean duration of residence in France (SD) | 9.88 (0–25.4) | NA | NA | |
| Range of duration of residence in France | 0–65 years | NA | NA | |
| ≥1 year | 220 (55.3) | 79 (35.9) | 141 (64.1) | 1.52 (0.99–2.32), p 0.06 |
| <1 year | 178 (44.7) | 48 (27.0) | 130 (73.0) | Ref |
| Visit to country of origin since immigration | 126 (31.9) | 51 (40.5) | 75 (59.5) | 1.76 (1.13–2.74), p 0.012 |
| No visits to country of origin since immigration | 269 (68.1) | 75 (27.9) | 194 (72.1) | Ref |
| Mean duration of homelessness (SD) | 2.66 years (0–7.8) | NA | NA | |
| Range of duration of homelessness | 0–52 years | |||
| ≥1 year | 175 (37.6) | 80 (45.7) | 95 (70.6) | 2.02 (1.37–2.99), p <0.0001 |
| <1 year | 290 (62.4) | 85 (29.4) | 204 (70.6) | Ref |
| Addiction | ||||
| Alcohol | ||||
| Frequent | 52 (10.9) | 24 (47.1) | 27 (52.9) | 1.75 (0.98–3.14), p 0.06 |
| Rare or never | 424 (89.1) | 143 (33.7) | 281 (66.3) | Ref |
| Tobacco | ||||
| Yes | 293 (61.2) | 113 (38.7) | 179 (61.3) | 1.48 (1.00–2.20), p 0.05 |
| Never | 185 (38.7) | 55 (30.3) | 129 (70.1) | Ref |
| Cannabis | 75 (15.7) | 28 (37.3) | 47 (62.7) | 1.11 (0.67–1.85), p 0.69 |
| Injected substances | 2 (0.4) | 0 (0) | 2 (100) | |
| Snorted substances | 13 (2.7) | 4 (30.8) | 9 (66.2) | |
| Drug substitutes | 1 (0.2) | 1 (100) | 0 (0) | |
| Chronic diseases | ||||
| Chronic respiratory diseases | 38 (8.1) | 27 (71.0) | 11 (28.9) | 5.12 (2.47–10.62), p <0.0001 |
| Diabetes mellitus | 36 (7.6) | 14 (38.9) | 22 (61.1) | 1.18 (0.59–2.37), p 0.65 |
| Cancer | 5 (1.1) | 1 (20) | 4 (80) | |
| Hepatitis | 10 (2.1) | 8 (80) | 2 (20) | |
| Body mass index (kg/m2) | ||||
| Mean body mass index | 24.4 ± 4.0 | NA | NA | |
| Range of Body mass index | ||||
| Normal weight | 251 (55.9) | 86 (34.3) | 165 (65.7) | Ref |
| Underweight | 17 (3.8) | 9 (52.9) | 8 (47.1) | 0.46 (0.17–0.24), p 0.12 |
| Overweight | 138 (30.7) | 47 (34.1) | 91 (65.9) | 1.00 (0.65–1.56), p 0.97 |
| Obesity | 43 (9.6) | 12 (27.9) | 31 (72.1) | 1.35 (0.65–2.75), p 0.41 |
| Seasonal vaccination against influenza | 71 (15.1) | 31 (43.7) | 40 (56.3) | 1.50 (0.90–2.5), p 0.12 |
| Respiratory carriage | ||||
| | 280 (59.6) | 90 (32.4) | 189 (67.7) | 0.73 (0.50–1.08), p 0.11 |
| | 59 (12.4) | 32 (54.2) | 27 (45.8) | 2.45 (1.42–4.29), p 0.001 |
| | 35 (7.3) | 10 (26.8) | 25 (71.4) | 0.72 (0.33–1.53), p 0.4 |
| | 35 (7.3) | 11 (31.4) | 24 (68.6) | 0.83 (0.40–1.75), p 0.63 |
| At least one virus | 51 (10.8) | 26 (51) | 25 (49) | 2.09 (1.17–3.49), p 0.012 |
| Human rhinovirus | 25 (5.3) | 11 (44) | 14 (56) | 1.48 (0.65–3.34), p 0.34 |
| Human coronavirus | 10 (2.1) | 5 (50) | 5 (50) | |
| Influenza A virus | 7 (1.5) | 4 (57.1) | 3 (42.9) | |
| Influenza B virus | 7 (1.5) | 5 (71.4) | 2 (28.6) | |
| Human respiratory syncytial virus | 3 (0.6) | 1 (33.3) | 2 (66.6) | |
| Human para-influenza virus | 1 (0.2) | 1 (100) | 0 | |
| Human metapneumovirus | 0 | 0 | 0 | |
| Co-infection | ||||
| | 43 (9.0) | 24 (55.8) | 19 (44.2) | 2.55 (1.35–4.82), p 0.003 |
| | 33 (7.0) | 14 (42.2) | 19 (57.6) | 1.4 (0.68–2.85), p 0.36 |
| | 25 (5.2) | 6 (24) | 19 (76) | 0.57 (0.22–1.45), p 0.23 |
| | 24 (5.0) | 8 (33.3) | 16 (66.7) | 0.92 (0.38–2.19), p 0.85 |
| | 12 (2.5) | 9 (75) | 3 (25) | |
| | 9 (1.9) | 4 (44.4) | 5 (55.6) | |
| | 5 (1.0) | 3 (60) | 2 (40) | |
| | 4 (0.8) | 0 | 4 (100) | |
| | 4 (0.8) | 3 (75) | 1 (25) | |
Abbreviations: SD, standard deviation; NA, not applicable, Ref, Reference category.
Year of study was not included in the analysis, given that no intervention could be done based on this criterion.
Fig. 1Prevalence of clinical signs and symptoms over the 2015–2017 period (n = 479 individuals). Abbreviations: CRDs, chronic respiratory diseases.
Prevalence (%) of bacteria and viruses detected by quantitative PCR
| Respiratory pathogen | Positive carriage | |||
|---|---|---|---|---|
| Nasal specimen, | Pharyngeal specimen, | p-value | Nasal or pharyngeal, | |
| Total | 476 (100) | 474 (100) | 477 (100) | |
| Bacteria | 105 (22.1) | 280 (59.1) | <0.0001 | 313 (65.6) |
| | 46 (9.8) | 266 (56.4) | <0.0001 | 280 (58.7) |
| | 17 (3.5) | 20 (4.2) | 0.61 | 35 (7.3) |
| | 28 (5.9) | 12 (2.5) | <0.001 | 35 (7.3) |
| | 33 (7.0) | 36 (7.6) | 0.69 | 59 (12.4) |
| Virus | 34 (7.1) | 24 (5.1) | 0.18 | 51 (10.8) |
| Influenza A virus | 4 (0.8) | 4 (1.0) | – | 7 (1.5) |
| Influenza B virus | 4 (0.8) | 6 (1.3) | – | 7 (1.5) |
| Human rhinovirus | 20 (4.3) | 7 (1.5) | <0.001 | 25 (5.3) |
| Human respiratory syncytial virus | 1 (0.2) | 2 (0.4) | – | 3 (0.6) |
| Human metapneumovirus | 0 (0) | 0 (0) | – | 0 (0) |
| Human coronavirus | 5 (1.1) | 5 (1.1) | 0.99 | 10 (2.1) |
| HCoV-HKU1 | 0 (0) | 1 (0.2) | – | 1 (0.2) |
| HCoV-E229 | 3 (0.6) | 1 (0.2) | – | 4 (0.8) |
| HCoV-NL63 | 1 (0.2) | 0 (0) | – | 1 (0.2) |
| HCoV-OC43 | 1 (0.2) | 3 (0.6) | – | 4 (0.8) |
| Human para-influenza virus | 0 (0) | 1 (0.2) | – | 1 (0.2) |
A total of 473 participants had both nasal and pharyngeal sampling; three participants had only nasal swabs and one had only pharyngeal swabs. Participants having at least one nasal or pharyngeal positive sample were considered positive cases.
Risk factors for respiratory disease: multivariate analysis
| Characteristics | Multivariate analysis |
|---|---|
| Odds ratio (95% CI), p-value | |
| Age ≥50 years versus others | |
| Birthplace | |
| Range of duration of residence in France ≥1 year versus others | |
| Visit to country of origin since immigration | 1.68 (1.04–2.71), p 0.035 |
| Range of duration of homelessness ≥1 year versus others | 1.77 (1.11–2.83), p 0.017 |
| Alcohol | – |
| Tobacco | – |
| Chronic respiratory diseases | 5.27 (2.24–12.41), p <0.0001 |
| Seasonal vaccination against influenza | – |
| Respiratory pathogen | |
| | – |
| | 2.32 (1.18–5.3), p 0.014 |
| At least one virus | 2.40 (1.21–4.74), p 0.012 |
| | – |
Only variables with p values <0.2 in the univariate analysis and with a paired correlation coefficient <0.7 were included in the multivariate analysis.
Association between respiratory pathogen carriage and clinical findings in univariate analysis according to respiratory symptoms and signs
| Respiratory pathogen | Odds ratio (95% CI), p-value | ||||
|---|---|---|---|---|---|
| Cough | Expectoration | Rhinorrhoea | Dyspnoea | Sore throat | |
| 2.5 (1.41–4.41), p 0.001 | 1.3 (0.59–2.95), p 0.51 | 1.03 (0.3–3.59) p 0.965 | 1.10 (0.41–2.95) p 0.85 | 1.13 (0.38–3.37), p 0.83 | |
| At least one virus | 2.5 (1.37–4.58), p 0.002 | 2.15 (1.01–4.60) p 0.044 | 2.5 (1.00–6.12), p 0.047 | 1.68 (0.66–4.24), p 0.27 | 7.3 (3.26–16.42), p <0.0001 |